Sinopharm Group Co Ltd operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Sinopharm Group Co Ltd with three other
drug stores in Asia:
Shanghai Pharmaceuticals Holding Co Ltd
sales of 130.85 billion Chinese Renmimbi [US$18.96 billion]
of which 86%
was Distribution segment),
Alfresa Holdings Corporation
(2.55 trillion Japanese Yen [US$22.51 billion]
of which 88%
was Wholesale Business of Pharmaceuticals fo), and
Medipal Holdings Corporation
based in Japan
(3.06 trillion Japanese Yen [US$27.02 billion]
of which 68%
was Pharmaceuticals And Food Precessing Whol).
During the year ended December of 2017, sales at
Sinopharm Group Co Ltd were 277.72 billion Chinese Renmimbi (US$40.25 billion).
increase of 7.5%
versus 2016, when the company's sales were 258.39 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Sinopharm Group Co Ltd
(and since 2012, sales have increased a total of 105%).
Sales of Retail Pharmacy Operations saw an increase
that was more than double the company's growth rate: sales were up
21.0% in 2017, from
10.20 billion Chinese Renmimbi to 12.34 billion Chinese Renmimbi.
Not all segments of Sinopharm Group Co Ltd experienced an increase in sales in 2017:
sales of Other Business Operations fell 13.1% to 3.74 billion Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).